Bruker (BRKR) vs Harvard Bioscience (HBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harvard Bioscience (HBIO) has outperformed Bruker (BRKR) over the past year, gaining 93.2% versus a gain of 72.8%. Over five years, BRKR leads with a -22.7% price change compared with -87.6% for HBIO. Bruker is the larger company by market cap ($8.80 billion vs $38.7 million), about 227.3 times the size.
On valuation, Harvard Bioscience trades at a lower forward P/E (13.2x vs 23.9x for Bruker). Bruker pays a dividend yielding 0.35%, while Harvard Bioscience does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | HBIO |
|---|---|---|
| Share price | $57.74 | $8.50 |
| Market cap | $8.80B | $38.69M |
| 1-day change | -3.32% | 0.00% |
| YTD return | +26.77% | +26.87% |
| 1-year return | +72.80% | +93.18% |
| 5-year return | -22.67% | -87.57% |
| Forward P/E | 23.93 | 13.18 |
| EPS (TTM) | $-0.70 | $-2.31 |
| Dividend yield | 0.35% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $3.44B | — |
| Revenue growth (YoY) | +2.08% | — |
| Net income (latest FY) | $-8.60M | — |
| Gross margin | 45.91% | — |
| Operating margin | 1.98% | — |
| Net margin | -0.25% | — |
| 52-week high | $66.98 | $9.40 |
| 52-week low | $32.37 | $3.80 |
| Distance from 52-week high | -13.80% | -9.57% |
| Analyst consensus | buy | — |
| Avg. price target upside | +9.55% | — |
| Average volume | 2.23M | 17.87K |
| Shares outstanding | 152.36M | 4.55M |
| Employees | 11,085 | — |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bruker is about 227.3 times larger than Harvard Bioscience by market value ($8.80B vs $38.69M).
- HBIO has outperformed BRKR by 20.4 percentage points over the past year.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
BRKR vs HBIO FAQ
Which is bigger, Bruker or Harvard Bioscience?
Bruker (BRKR) is larger, with a market capitalization of $8.80B compared with $38.69M for Harvard Bioscience (HBIO).
Which stock has performed better over the past year, BRKR or HBIO?
HBIO returned +93.18% over the past 12 months, compared with +72.80% for BRKR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Harvard Bioscience?
Bruker pays a dividend yielding 0.35%, while Harvard Bioscience does not currently pay a regular dividend.
Are Bruker and Harvard Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.